Shares of Park Ha Biological Technology slid 14.1% to $1.27 after the Wuxi, China-based micro-cap confirmed it closed a $2.0 million registered direct offering — its second capital raise this year. For a company already running heavy cumulative losses, the deal keeps the lights on but punishes the shareholders footing the bill.
Over 1.3 Million New Shares Flood a Paper-Thin Market
The company sold up to 1,133,332 Class A ordinary shares plus pre-funded warrants covering another 200,000 shares, all priced at $1.50 per unit. That price sat just above the prior close of $1.47 on June 12 — the day the deal was announced — but today's $1.27 print means investors who bought the offering are already underwater. In a stock this small, where price is "driven by sentiment and liquidity," dumping over a million new shares into circulation amplifies every downtick.
This Is the Second Dilutive Deal in Five Months
Back in January, Park Ha closed a US$2.45 million public offering of 21,875,000 units at just $0.112 each — a far lower price point that massively expanded the share count. Those proceeds were earmarked for expanding directly operated stores in China. Now, barely five months later, the company says this round's net proceeds will go toward "working capital and other general corporate purposes" — a vague label that offers shareholders no visibility into a concrete growth plan.
A Wild Price Spike Created a Convenient Window to Sell Stock
BYAH had exploded from a tight $1.10–$1.25 range into a spike above $3, with shares up over 165% intraday on June 12. The shelf registration was declared effective by the SEC on June 8, 2026 — just days before the spike — meaning the company was legally positioned to sell stock the moment the price popped. Park Ha carries "a small revenue base, decent cash, and relatively low debt, yet the company has piled up heavy cumulative losses."
Vague Strategy Adds to Investor Uncertainty
On the same day it priced the offering, Park Ha announced a strategic partnership with a Hong Kong–listed firm to combine AI technology, skincare, and celebrity branding.
Their first product — an AI-powered nutrition tool — launched as a pilot. Whether that translates to meaningful revenue remains entirely speculative. With repeated dilution, negligible earnings power, and a strategy that reads more like a press release than a business plan, BYAH shareholders are paying the price — literally — while the company buys itself more time.